title: Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data.
abstract: The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced into the routine immunization program in Uruguay in March 2008 with a 2-dose primary series (given at 2 and 4 months) plus a booster (at 12 months) and a catch-up campaign (two doses given at 15 and 17 months). We used a case-control methodology and existing laboratory surveillance and immunization registry data from Uruguay to evaluate PCV7 effectiveness against vaccine-type invasive pneumococcal disease (VT-IPD). Cases of VT-IPD (with pneumococcus obtained from a normally sterile site) were identified through the National Reference Laboratory. Age- and neighborhood-matched controls were obtained through a national immunization registry in which all children are enrolled at birth regardless of vaccine receipt; all eligible controls were included. Immunization status of cases and controls was assessed through the immunization registry, and conditional logistic regression was used to calculate PCV7 effectiveness. Between April 2008 and February 2010, 44 cases of VT-IPD among children<5 years were identified; 43 (98%) of those children were located in the registry. Among located case patients, 7 (16.3%) were age-eligible to have received at least one dose of PCV7. A total of 637 matched controls were included. Vaccine effectiveness was 91.3% (95% CI: 46.4, 98.6) for ≥ 1 PCV7 doses and 94.8% (95% CI: 43.1, 99.5) for ≥ 2 PCV7 doses. Using existing data we demonstrated high effectiveness of PCV7 against VT-IPD in Uruguay-a middle-income country using a 2-dose primary series plus a booster dose and a limited catch-up campaign. These data also highlight the utility of surveillance and high-quality immunization registries for evaluating the effectiveness of vaccines.
authors.affiliation: Immunization Unit, Epidemiology Division, Ministry of Public Health, Montevideo, Uruguay.
authors.forename: Teresa
authors.initials: T
authors.lastname: Picón
authors.forename: Lucía
authors.initials: L
authors.lastname: Alonso
authors.forename: Gabriela
authors.initials: G
authors.lastname: García Gabarrot
authors.forename: Noelia
authors.initials: N
authors.lastname: Speranza
authors.forename: Mariana
authors.initials: M
authors.lastname: Casas
authors.forename: Fernando
authors.initials: F
authors.lastname: Arrieta
authors.forename: Teresa
authors.initials: T
authors.lastname: Camou
authors.forename: Raquel
authors.initials: R
authors.lastname: Rosa
authors.forename: Lucia Helena
authors.initials: LH
authors.lastname: De Oliveira
authors.forename: Jennifer Rabke
authors.initials: JR
authors.lastname: Verani
mesh_terms: D016022:Case-Control Studies; D002675:Child, Preschool; D005260:Female; D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data*; D007117:Immunization, Secondary; D007223:Infant; D016015:Logistic Models; D008297:Male; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000627:therapeutic use*; D062486:Public Health Surveillance; D012042:Registries; D014583:Uruguay / Q000453:epidemiology
chemical_list: D000069443:Heptavalent Pneumococcal Conjugate Vaccine; D022242:Pneumococcal Vaccines